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Introduction
Typhoid fever is an important public-health problem
in Bangladesh. Salmonella enterica serovar Typhi and
Paratyphi are common etiological agents of typhoid.
With the emergence of resistance to ampicillin,
chloramphenicol and cotrimoxazole, first choice of
empiric treatment of typhoid fever has changed to
ciprofloxacin and ceftriaxone.1-3 But there are reports
of appearance of ciprofloxacin resistant salmonella
from Bangladesh and other countries.4,5 Resistance to
ceftriaxone has also been reported from Bangladesh in
1999.6 Recently, there is emergence of salmonella
strains that are ciprofloxacin sensitive but nalidixic
acid resistant. Treatment of these strains with the usual
dose of ciprofloxacin resulted in poor clinical outcome
as well as treatment failure.7-10 All these reports
suggest that fluoroquinolones should no longer be used
as the first-line therapy in populations where nalidixic
acid resistance is common among isolates of S. Typhi.
Moreover, recent studies indicate that the proportion
of S. Paratyphi is increasing over the years in the
subcontinent.11,12 Therefore, it is important to know
the species of Salmonella that are prevalent in a country
and the antibiotic susceptibility pattern of that prevalent
Salmonella sp.
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Abstract
The antibiotic resistance pattern of salmonella is ever changing over time. The present study is a
retrospective analysis of rate of isolation of Salmonella Typhi and Paratyphi and their antibiotic
resistance pattern over 6 years period in an urban hospital of Dhaka city.  Blood culture submitted
in BIRDEM hospital from 2004-2009 were analyzed. Isolated Salmonella sp were identified and
antimicrobial susceptibility testing was carried out by a standard disc diffusion method.
Among 385 isolated Salmonella sp 304 (79%) were Salmonella enterica serovar Typhi and 81 (21%)
were Salmonella enterica serover Paratyphi A. The rate of isolation of S. Paratyphi A has increased
over 6 the year period from 14% to 24%. Resistance to individual first line anti-salmonella drugs
has increased from 2004 to 2006 (42 to 63%) but has decreased thereafter. Similar pattern was found
when simultaneous resistance to three first line antibiotics namely ampicillin, chloramphenicol and
co-trimoxazole were considered. Out of total 304 S. Typhi, 117 (38%) were simultaneously resistant
to all three first line drugs compared to only 1.8% S. Paratyphi A. Analysis showed that 80 to 90%
of isolated S. Typhi was nalidixic acid resistant (NARST) with reduced susceptibility to ciprofloxacin
while the rate for  S. Paratyphi A was 71-94%. All S. Typhi and Paratyphi A were sensitive to
ceftriaxone. The study showed that there was a gradual decline of resistance of S. Typhi to first line
antibiotics but very high prevalence of nalidixic acid resistant S. Typhi and S. Paratyphi in Bangladesh.
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The present study investigated the trend of isolation of
Salmonella species responsible for typhoid fever and
their antibiotic resistance pattern over the last six
years (2004-2009) in urban area of Dhaka city.
Materials and Methods
A retrospective analysis of Salmonella Typhi and
Paratyphi isolated from patients attending BIRDEM
hospital during  2004 to 2009  was carried out.
BIRDEM hospital is a 600 bed tertiary care referral
hospital in Dhaka city. All the isolates were identified
by colony morphology, standard biochemical reactions
and by agglutination with specific antiserum.13 The
isolates were tested for susceptibility to ciprofloxacin
5µg, nalidixic acid 30 µg, chloramphenicol 30 µg, co-
trimoxazole 25 µg, ampicillin 10 µg, cefepime30 µg
and ceftriaxone 30 µg by a disk diffusion technique as
recommended by the NCCLS guideline.14 All disks
were obtained from Oxoid Ltd, Basingstoke,
Hampshire, UK. Potency of the disks and antibiotics
were standardized using the reference strain E. coli
ATCC 25922.
Results
A total of 385 Salmonella were isolated from blood
cultures over the period of 6 years. S. Typhi was the
predominant serotype followed by Salmonella Paratyphi
A (Table-1). The isolation rate of S. Typhi has gradually
decreased where as that of S. Paratyphi A has increased
over last six years.
Single and multi drug resistance to 3 first line
antibiotics namely ampicillin, chloramphenicol and
cotrimoxazole of isolated S. Typhi during 2004 to 2009
is shown in Fig-1. There was a gradual decline of
resistance to ampicillin, chloramphenicol and
cotrimoxazole since 2007 onwards. The overall
simultaneous resistance to three first line anti-
salmonella antibiotics namely ampicillin,
chloramphenicol and co-trimoxazole of isolated S.
Typhi during 2004-2009 was 38% (117 out of 304) and
the range was between 30-50%. Simultaneous
resistance to first line drugs in S. Typhi showed an
upward trend up to 2006 and then went downwards.
The resistant pattern of S. Paratyphi A from 2007 to
2009 is shown in Fig 2. But its resistance pattern  from
2004 to 2006 has not been shown as there were few
isolates. The resistance of S. Paratyphi A to ampicillin,
chloramphenicol and cotrimoxazole were low (5-20%)
compared to S. Typhi. The rate of multi drug resistance
Table-1: Species distribution of Salmonella sp. isolated
between 2004- 2009
Year Total number Salmonella Salmonella
of Salmonella Typhi Paratyphi A
Number % Number (%)
2004 51 44 86 7 14
2005 31 26 84 5 16
2006 83 70 84 13 16
2007 87 68 78 19 22
2008 65 44 68 21 32
2009 68 52 76 16 24
Total 385 304 79 81 21
Fig-1: Single and multi drug resistance rate to 3 first line
antibiotics namely ampicillin (AMP), chloramphenicol
(CHLO) and cotrimoxazole (SXT) of isolated S. Typhi
during 2004-2009. Note: 3 drugs indicate concurrent
resistance to AMP, CHLO and SXT
Fig-2: The resistance pattern of isolated S. Paratyphi A
to three first line anti- antibiotics during 2007-2009.
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of S. Paratyphi A has not been shown in Fig-2 also as
there were small number of isolates per year. However,
multi drug resistance in S. Paratyphi A was almost
absent and static during the period. Only 1(1.3%) out
of 81 isolates in S. Paratyphi A was resistant to three
first line antibiotics simultaneously during the same
period. No ceftriaxone resistant S. Typhi or Paratyphi
was detected during the six year period. However, the
resistance to cefixime, a third generation
cephalosporin, of S. Typhi and S. Paratyphi A ranged
from 12-28% and 7-29% during 2004-2009 and 2007-
2009  respectively.
Table-2 shows that 80-100% of the isolated S. Typhi
and 75-94% of S. Paratyphi A were nalidixic acid
resistant. There were no remarkable changes in the
resistance pattern of S. Typhi and S. Paratyphi A to
nalidixic acid in last 6 years. Only few isolates of S.
Typhi were found fully resistant to ciprofloxacin during
the period.
Discussion
Typhoid fever is endemic in Bangladesh.16 The present
study was conducted as a part of the continuous
surveillance about the prevalence of Salmonella sp and
their antimicrobial susceptibility pattern which was
very important to institute appropriate antimicrobial
therapy. The study revealed that there was gradual
emergence of S. Paratyphi A during the period as a
cause of typhoid fever. Among the total isolated
salmonella, S. Typhi was about 79% where as S.
Paratyphi A was 21%. The proportion of S. Paratyphi
A had increased over 6 years from 14% in 2004 to
24% in 2009. Similar emergence of S. Paratyphi A in
subcontinent has been reported.11,12
The number of S. Typhi simultaneously resistant to all
three first line drugs namely ampicillin,
chloramphenicol and cotrimoxazole declined towards
2007 and continued through 2009. It might be due to
the loss of unstable resistant gene resulting from
removal of selection pressure of these antibiotics.15
Re-emergence of the sensitivity to these drugs were
also reflected from the individual upward trend of
sensitivity pattern through recent years. S. paratyphi
A showed moderate to high sensitivity to those drugs
through out the last six years and there was only one
multi drug resistant isolate out of total 81 isolates.
With the emergence of salmonella strains resistant to
the first line drugs, quinolones and third generation
cephalosporin (ceftriaxone and cefixime) are
extensively being used in the treatment of typhoid fever
during last decade. But, no ceftriaxone resistant isolate
was found during the six years study period. However,
7-28% S. Typhi and S. Paratyphi A were resistant to
cefixime.
Ciprofloxacin is being used as the first choice of
empiric treatment of typhoid in Bangladesh for last
several years. But the current study revealed that about
80-100% of S. typhi and S. Paratyphi A were resistant
to nalidixic acid. The treatment of typhoid due to
nalidixic acid resistant Salmonella sp with ciprofloxacin
is less effective as there were reports of treatment
failures from Bangladesh and other countries.7-10 It
was due to higher minimum inhibitory concentration
of ciprofloxacin of these isolates. Nalidixic acid
resistant S. Typhi had been reported to have higher
minimum inhibitory concentration of ciprofloxacin
compared to susceptible strains.10 So, it has been
recommended that quinolones should not be used as
the first-line therapy in populations like Bangladesh
where nalidixic acid resistance is common among
isolates of salmonella. However, gatifloxacin may be
used as alternative as because it has different
mechanism to develop resistance than that of
ciprofloxacin.17
Thus, our study indicates that the isolation of S.
Paratyphi A is increasing over the years and the
resistance to antibiotics among S. Typhi and S.
Paratyphi is rising in our country. On the other hand,
there has been a re-emergence of sensitivity to first
line anti-salmonella drugs like ampicillin,
Table-2: Rate of isolation of nalidixic acid resistant S.
Typhi and S. Paratyphi A from 2004-2009.
Total S. Typhi NARST S.Paratyphi NARSPT
Year Number of A
Salmonella N N % N N %
2004 48 41 33 80.5 7 6 86
2005 27 23 23 100 4 3 75
2006 64 54 49 91 10 9 90
2007 70 53 47 89 17 12 71
2008 65 44 39 89 21 19 90
2009 68 52 46 88 16 15 94
Total 342 267 237 88.8 79 64 81.0
NARST= nalidixic acid resistant S. Typhi; NARSPT= nalidixic acid
resistant S. Paratyphi
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chloramphenicol and cotrimoxazole. Nalidixic acid
resistant organisms should be screened routinely to detect
organisms with reduced susceptibility to ciprofloxacin
to avoid treatment failure with quinolone therapy.
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